– Reuters
Canaccord Genuity Downgrades Maxar Technologies to Hold
Canaccord Genuity analyst Austin Moeller downgrades Maxar Technologies (NYSE:MAXR) from Buy to Hold.
Related Posts
Theravance Biopharma Q2 EPS $(0.04) Up From $(0.80) YoY, Sales $11.05M Miss $12.41M Estimate
Theravance Biopharma (NASDAQ:TBPH) reported quarterly losses of $(0.04) per share. This is a 95 percent increase over losses of $(0.80) per share from the same period last year. The company reported quarterly sales of
$1000 Invested In This Stock 15 Years Ago Would Be Worth $3,100 Today
Intercontinental Exchange (NYSE:ICE) has outperformed the market over the past 15 years by 1.68% on an annualized basis producing an average annual return of 7.83%. Currently, Intercontinental Exchange has a market capitalization of $54.02 billion.